首页 > 最新文献

Journal of the National Comprehensive Cancer Network最新文献

英文 中文
Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer. 青少年癌症患者在确诊时的生活质量报告。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-12 DOI: 10.6004/jnccn.2024.7012
Goldy C George, Clark Andersen, Xiaohui Tang, Elizabeth Rodriguez, Midhat Jafry, Maria C Swartz, Sairah Ahmed, Carlos H Barcenas, J Andrew Livingston, Michael E Roth, Michelle A T Hildebrandt

Background: The overall landscape of health-related quality of life (HRQoL) has not been thoroughly investigated in adolescents and young adults (AYAs) with cancer. Data are also lacking on how well HRQoL at the time of cancer diagnosis can prognosticate long-term survival in AYA survivors.

Patients and methods: We included 3,497 survivors of AYA cancer (age 15-39 years at diagnosis) who completed the Short-Form 12 Health Survey (SF-12) HRQoL questionnaire at diagnosis. Physical component summary (PCS) and mental component summary (MCS) scores were generated, with scores <50 representing poor HRQoL. Differences in HRQoL by patient characteristics and tumor type were investigated using violin plots and t tests/analysis of variance. The effect of HRQoL on overall survival was assessed using Kaplan-Meier plots and Cox proportional hazards models.

Results: Overall mean PCS and MCS scores in this racially/ethnically diverse cohort (64% White, 19% Hispanic, 10% Black, and 7% other race/ethnicity) were 43.6 and 46.7, respectively. Women with breast cancer reported the most favorable PCS (50.8), and those with cervical cancer reported the lowest MCS (42.8). Age at diagnosis was associated positively with PCS (P<.001) and inversely with MCS (P<.001). Females had higher PCS yet lower MCS than males (both P<.001). Marginalized racial and ethnic populations reported lower PCS than White patients (P<.001). Physical and mental HRQoL were prognostic and associated with increased risk of poor survival (hazard ratio, 1.95; 95% CI, 1.72-2.21 for physical HRQoL, and 1.26; 95% CI, 1.13-1.40 for mental HRQoL).

Conclusions: Physical and mental HRQoL at diagnosis vary across patient characteristics in AYA cancer survivors. Poor HRQoL at diagnosis may be a prognosticator of diminished overall survival among AYA cancer survivors.

背景:对于青少年和年轻成人癌症患者的健康相关生活质量(HRQoL)的整体情况尚未进行深入研究。此外,关于癌症确诊时的 HRQoL 如何预示青少年癌症幸存者的长期生存率,也缺乏相关数据:我们纳入了 3,497 名青少年癌症幸存者(确诊时年龄为 15-39 岁),他们在确诊时填写了短表 12 健康调查(SF-12)HRQoL 问卷。得出了身体成分汇总 (PCS) 和精神成分汇总 (MCS) 分数,并得出了评分 结果:在这个种族/族裔多元化的群体(64% 白人、19% 西班牙裔、10% 黑人和 7% 其他种族/族裔)中,PCS 和 MCS 的总平均分分别为 43.6 分和 46.7 分。乳腺癌妇女的 PCS 值最高(50.8),宫颈癌妇女的 MCS 值最低(42.8)。确诊时的年龄与 PCS 呈正相关(PConclusions:不同年龄段癌症幸存者在确诊时的身体和心理 HRQoL 因患者特征而异。诊断时不良的 HRQoL 可能是导致青少年癌症幸存者总生存率下降的预兆因素。
{"title":"Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer.","authors":"Goldy C George, Clark Andersen, Xiaohui Tang, Elizabeth Rodriguez, Midhat Jafry, Maria C Swartz, Sairah Ahmed, Carlos H Barcenas, J Andrew Livingston, Michael E Roth, Michelle A T Hildebrandt","doi":"10.6004/jnccn.2024.7012","DOIUrl":"10.6004/jnccn.2024.7012","url":null,"abstract":"<p><strong>Background: </strong>The overall landscape of health-related quality of life (HRQoL) has not been thoroughly investigated in adolescents and young adults (AYAs) with cancer. Data are also lacking on how well HRQoL at the time of cancer diagnosis can prognosticate long-term survival in AYA survivors.</p><p><strong>Patients and methods: </strong>We included 3,497 survivors of AYA cancer (age 15-39 years at diagnosis) who completed the Short-Form 12 Health Survey (SF-12) HRQoL questionnaire at diagnosis. Physical component summary (PCS) and mental component summary (MCS) scores were generated, with scores <50 representing poor HRQoL. Differences in HRQoL by patient characteristics and tumor type were investigated using violin plots and t tests/analysis of variance. The effect of HRQoL on overall survival was assessed using Kaplan-Meier plots and Cox proportional hazards models.</p><p><strong>Results: </strong>Overall mean PCS and MCS scores in this racially/ethnically diverse cohort (64% White, 19% Hispanic, 10% Black, and 7% other race/ethnicity) were 43.6 and 46.7, respectively. Women with breast cancer reported the most favorable PCS (50.8), and those with cervical cancer reported the lowest MCS (42.8). Age at diagnosis was associated positively with PCS (P<.001) and inversely with MCS (P<.001). Females had higher PCS yet lower MCS than males (both P<.001). Marginalized racial and ethnic populations reported lower PCS than White patients (P<.001). Physical and mental HRQoL were prognostic and associated with increased risk of poor survival (hazard ratio, 1.95; 95% CI, 1.72-2.21 for physical HRQoL, and 1.26; 95% CI, 1.13-1.40 for mental HRQoL).</p><p><strong>Conclusions: </strong>Physical and mental HRQoL at diagnosis vary across patient characteristics in AYA cancer survivors. Poor HRQoL at diagnosis may be a prognosticator of diminished overall survival among AYA cancer survivors.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer. 胃食管癌患者化疗引起的周围神经病变
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-08 DOI: 10.6004/jnccn.2024.7014
Merel J M van Velzen, Marieke Pape, Mirjam A G Sprangers, Jessy Joy van Kleef, Bianca Mostert, Laurens V Beerepoot, Marije Slingerland, Elske C Gootjes, Ronald Hoekstra, Lonneke V van de Poll-Franse, Nadia Haj Mohammad, Hanneke W M van Laarhoven

Background: Chemotherapy for various stages of gastroesophageal cancer (GEC) is often neurotoxic. Chemotherapy-induced peripheral neuropathy (CIPN) impairs health-related quality of life (HRQoL). This study investigates the incidence and severity of CIPN and its association with HRQoL in patients with GEC.

Patients and methods: Patients who received chemoradiotherapy or chemotherapy for GEC were identified from the Netherlands Cancer Registry. Patient-reported data (measured using the EORTC QLQ-CIPN20 and EORTC QLQ-C30) were collected through the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP) at baseline and at 3, 6, 9, 12, 18, and 24 months after treatment initiation. Linear mixed effects models were constructed to assess CIPN and the correlation between CIPN and HRQoL was analyzed using Spearman's correlation.

Results: A total of 2,135 patients were included (chemoradiotherapy: 1,593; chemotherapy with curative intent: 295; palliative chemotherapy: 247). In all 3 treatment groups, CIPN significantly increased during treatment (adjusted mean score of CIPN at 6 months: chemoradiotherapy, 8.3 [baseline: 5.5]; chemotherapy with curative intent, 16.0 [baseline: 5.6]; palliative therapy, 25.4 [baseline: 10.7]). For chemoradiotherapy, the adjusted mean score continued to increase after treatment (24 months: 11.2). For chemotherapy with curative intent and palliative therapy, the adjusted mean score of CIPN decreased after treatment but did not return to baseline values. CIPN was negatively correlated with HRQoL in all treatment groups, although significance and strength of the correlation differed over time.

Conclusions: Because of the poor prognosis of GEC, it is essential to consider side effects of (neurotoxic) treatment. The high prevalence and association with HRQoL indicate the need for early recognition of CIPN.

背景:针对不同阶段胃食管癌(GEC)的化疗通常具有神经毒性。化疗引起的周围神经病变(CIPN)会损害健康相关生活质量(HRQoL)。本研究调查了化疗诱发周围神经病变的发生率、严重程度及其与胃食管癌患者 HRQoL 的关系:患者和方法:从荷兰癌症登记处确定了接受化放疗或化疗的 GEC 患者。患者报告数据(使用 EORTC QLQ-CIPN20 和 EORTC QLQ-C30 测量)是通过食管胃癌患者前瞻性观察队列研究(POCOP)在基线和治疗开始后 3、6、9、12、18 和 24 个月收集的。建立线性混合效应模型来评估CIPN,并使用斯皮尔曼相关性分析CIPN与HRQoL之间的相关性:共纳入2135名患者(化放疗:1593人;治愈性化疗:295人;姑息性化疗:295人):295例;姑息化疗247例)。在所有 3 个治疗组中,CIPN 在治疗期间均显著增加(6 个月时的 CIPN 调整后平均得分:化放疗,8.3 [基线:5.5];治愈性化疗,16.0 [基线:5.6];姑息治疗,25.4 [基线:10.7])。化疗放疗的调整后平均得分在治疗后继续上升(24 个月:11.2)。对于治愈性化疗和姑息治疗,CIPN的调整后平均得分在治疗后有所下降,但没有恢复到基线值。在所有治疗组中,CIPN与HRQoL均呈负相关,但相关性的显著性和强度随时间推移而不同:结论:由于 GEC 预后不良,因此必须考虑(神经毒性)治疗的副作用。高发病率以及与 HRQoL 的相关性表明,有必要及早识别 CIPN。
{"title":"Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.","authors":"Merel J M van Velzen, Marieke Pape, Mirjam A G Sprangers, Jessy Joy van Kleef, Bianca Mostert, Laurens V Beerepoot, Marije Slingerland, Elske C Gootjes, Ronald Hoekstra, Lonneke V van de Poll-Franse, Nadia Haj Mohammad, Hanneke W M van Laarhoven","doi":"10.6004/jnccn.2024.7014","DOIUrl":"10.6004/jnccn.2024.7014","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy for various stages of gastroesophageal cancer (GEC) is often neurotoxic. Chemotherapy-induced peripheral neuropathy (CIPN) impairs health-related quality of life (HRQoL). This study investigates the incidence and severity of CIPN and its association with HRQoL in patients with GEC.</p><p><strong>Patients and methods: </strong>Patients who received chemoradiotherapy or chemotherapy for GEC were identified from the Netherlands Cancer Registry. Patient-reported data (measured using the EORTC QLQ-CIPN20 and EORTC QLQ-C30) were collected through the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP) at baseline and at 3, 6, 9, 12, 18, and 24 months after treatment initiation. Linear mixed effects models were constructed to assess CIPN and the correlation between CIPN and HRQoL was analyzed using Spearman's correlation.</p><p><strong>Results: </strong>A total of 2,135 patients were included (chemoradiotherapy: 1,593; chemotherapy with curative intent: 295; palliative chemotherapy: 247). In all 3 treatment groups, CIPN significantly increased during treatment (adjusted mean score of CIPN at 6 months: chemoradiotherapy, 8.3 [baseline: 5.5]; chemotherapy with curative intent, 16.0 [baseline: 5.6]; palliative therapy, 25.4 [baseline: 10.7]). For chemoradiotherapy, the adjusted mean score continued to increase after treatment (24 months: 11.2). For chemotherapy with curative intent and palliative therapy, the adjusted mean score of CIPN decreased after treatment but did not return to baseline values. CIPN was negatively correlated with HRQoL in all treatment groups, although significance and strength of the correlation differed over time.</p><p><strong>Conclusions: </strong>Because of the poor prognosis of GEC, it is essential to consider side effects of (neurotoxic) treatment. The high prevalence and association with HRQoL indicate the need for early recognition of CIPN.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NCCN News NCCN 新闻
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.6004/jnccn.2024.0039
{"title":"NCCN News","authors":"","doi":"10.6004/jnccn.2024.0039","DOIUrl":"https://doi.org/10.6004/jnccn.2024.0039","url":null,"abstract":"","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence and Oncology. 人工智能与肿瘤学。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.6004/jnccn.2024.0037
Daniel M Geynisman
{"title":"Artificial Intelligence and Oncology.","authors":"Daniel M Geynisman","doi":"10.6004/jnccn.2024.0037","DOIUrl":"10.6004/jnccn.2024.0037","url":null,"abstract":"","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. 乳腺癌,3.2024 版,NCCN 肿瘤学临床实践指南。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.6004/jnccn.2024.0035
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Bethany Anderson, Janet Bailey, Harold J Burstein, Nan Chen, Helen Chew, Chau Dang, Anthony D Elias, Sharon H Giordano, Matthew P Goetz, Rachel C Jankowitz, Sara H Javid, Jairam Krishnamurthy, A Marilyn Leitch, Janice Lyons, Susie McCloskey, Melissa McShane, Joanne Mortimer, Sameer A Patel, Laura H Rosenberger, Hope S Rugo, Cesar Santa-Maria, Bryan P Schneider, Mary Lou Smith, Hatem Soliman, Erica M Stringer-Reasor, Melinda L Telli, Mei Wei, Kari B Wisinski, Kay T Yeung, Jessica S Young, Ryan Schonfeld, Rashmi Kumar

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

乳腺癌的治疗采用多学科方法,包括肿瘤外科、肿瘤放射科和肿瘤内科。NCCN 肿瘤学临床实践指南》(NCCN Guidelines)中关于乳腺癌的内容包括原位癌、浸润性乳腺癌、Paget 病、Phyllodes 肿瘤、炎症性乳腺癌患者的临床治疗建议,以及妊娠期乳腺癌的治疗建议。本期内容的重点是对非转移性乳腺癌全身治疗(术前和辅助治疗)方案的整体管理提出建议。欲了解完整版《NCCN 乳腺癌指南》,请访问 NCCN.org。
{"title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.","authors":"William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Bethany Anderson, Janet Bailey, Harold J Burstein, Nan Chen, Helen Chew, Chau Dang, Anthony D Elias, Sharon H Giordano, Matthew P Goetz, Rachel C Jankowitz, Sara H Javid, Jairam Krishnamurthy, A Marilyn Leitch, Janice Lyons, Susie McCloskey, Melissa McShane, Joanne Mortimer, Sameer A Patel, Laura H Rosenberger, Hope S Rugo, Cesar Santa-Maria, Bryan P Schneider, Mary Lou Smith, Hatem Soliman, Erica M Stringer-Reasor, Melinda L Telli, Mei Wei, Kari B Wisinski, Kay T Yeung, Jessica S Young, Ryan Schonfeld, Rashmi Kumar","doi":"10.6004/jnccn.2024.0035","DOIUrl":"10.6004/jnccn.2024.0035","url":null,"abstract":"<p><p>Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024. NCCN Guidelines® Insights:黑色素瘤:皮肤,2.2024 版。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.6004/jnccn.2024.0036
Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni, Joel Baumgartner, Shailender Bhatia, Christopher Bichakjian, Genevieve Boland, Sunandana Chandra, Bartosz Chmielowski, Dominick DiMaio, Roxana Dronca, Ryan C Fields, Martin D Fleming, Anjela Galan, Samantha Guild, John Hyngstrom, Giorgos Karakousis, Kari Kendra, Maija Kiuru, Julie R Lange, Ryan Lanning, Theodore Logan, Daniel Olson, Anthony J Olszanski, Patrick A Ott, Merrick I Ross, Luke Rothermel, April K Salama, Rohit Sharma, Joseph Skitzki, Emily Smith, Katy Tsai, Evan Wuthrick, Yan Xing, Nicole McMillian, Sara Espinosa

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.

NCCN 皮肤黑色素瘤指南》(全称 Melanoma: Cutaneous)为患者的诊断、分期和治疗提供了多学科建议。这些《NCCN指南透视》重点关注新辅助系统治疗方案的更新,并总结了NCCN专家组针对《NCCN皮肤黑色素瘤指南》2.2024版中推荐疗法所评估的新临床数据。
{"title":"NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.","authors":"Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni, Joel Baumgartner, Shailender Bhatia, Christopher Bichakjian, Genevieve Boland, Sunandana Chandra, Bartosz Chmielowski, Dominick DiMaio, Roxana Dronca, Ryan C Fields, Martin D Fleming, Anjela Galan, Samantha Guild, John Hyngstrom, Giorgos Karakousis, Kari Kendra, Maija Kiuru, Julie R Lange, Ryan Lanning, Theodore Logan, Daniel Olson, Anthony J Olszanski, Patrick A Ott, Merrick I Ross, Luke Rothermel, April K Salama, Rohit Sharma, Joseph Skitzki, Emily Smith, Katy Tsai, Evan Wuthrick, Yan Xing, Nicole McMillian, Sara Espinosa","doi":"10.6004/jnccn.2024.0036","DOIUrl":"10.6004/jnccn.2024.0036","url":null,"abstract":"<p><p>The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Tests in Pancreatic Cancer: Critical Role of Molecular Testing, Expanding Access, and Adherence to the NCCN Guidelines for Pancreatic Cancer. 胰腺癌分子检测:胰腺癌分子检测的关键作用、扩大使用范围以及遵守 NCCN 指南。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 DOI: 10.6004/jnccn.2024.7050
Nirag Jhala, Jeffrey Petersen, Darshana Jhala
{"title":"Molecular Tests in Pancreatic Cancer: Critical Role of Molecular Testing, Expanding Access, and Adherence to the NCCN Guidelines for Pancreatic Cancer.","authors":"Nirag Jhala, Jeffrey Petersen, Darshana Jhala","doi":"10.6004/jnccn.2024.7050","DOIUrl":"10.6004/jnccn.2024.7050","url":null,"abstract":"","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in New Patient Consultations During the COVID-19 Pandemic at a Canadian Comprehensive Cancer Center. 加拿大综合癌症中心在 COVID-19 大流行期间新患者就诊情况的变化。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.6004/jnccn.2024.7003
Carly C Barron, Tyler Pittman, Wei Xu, Mary Madunic, Niki Agelastos, David Goldstein, James Brierley, Monika K Krzyzanowska

Background: The impact of COVID-19 pandemic-related disruptions on cancer services is emerging. We evaluated the impact of the first 2 years of the pandemic on new patient consultations for all cancers at a comprehensive cancer center within a publicly funded health care system and assessed whether there was evidence of stage shift.

Methods: We performed a retrospective study using the Princess Margaret Cancer Registry. New consultations with medical, radiation, or surgical oncology were categorized by year and quarter. Logistic regression was used to assess the effect of period before and during the COVID-19 pandemic on cancer stage at consultation, adjusting for age, sex, and diagnosis location (our hospital network vs elsewhere).

Results: In all, 53,759 new patient consultations occurred from January 1, 2018, to June 30, 2022. After the pandemic was declared, there was a decrease in all types of consultations by 43.3% in the second quarter of 2020, and referral volumes did not recover during the first year. There was no evidence of stage shift for all cancer types during the later quarters of the pandemic for the overall population.

Conclusions: New patient consultations decreased across cancer stages, referral type, and most disease sites at our tertiary cancer center. We did not observe evidence of stage shift in this population. Further research is needed to determine whether this reflects the resilience of our health care system in maintaining cancer services or a delay in the presentation of advanced cancer cases. These data are important for shaping future cancer care delivery and recovery strategies.

背景:与 COVID-19 大流行相关的干扰对癌症服务的影响正在显现。我们评估了大流行头两年对公立医疗系统内一家综合癌症中心所有癌症新患者就诊的影响,并评估是否存在阶段性转移的证据:我们利用玛格丽特公主癌症登记处进行了一项回顾性研究。我们按年份和季度对肿瘤内科、放射科或外科的新就诊病例进行了分类。使用逻辑回归评估 COVID-19 大流行之前和期间对就诊时癌症分期的影响,并对年龄、性别和诊断地点(本医院网络与其他医院网络)进行调整:2018年1月1日至2022年6月30日期间,共有53759名新患者就诊。大流行宣布后,2020 年第二季度各类咨询量减少了 43.3%,转诊量在第一年内没有恢复。在大流行后期的几个季度中,没有证据表明所有癌症类型的总体人群都发生了分期转移:结论:在我们的三级癌症中心,不同癌症阶段、转诊类型和大多数疾病部位的新患者就诊量都有所下降。我们没有在这一人群中观察到分期转移的证据。我们需要进一步研究,以确定这是否反映了我们的医疗保健系统在维持癌症服务方面的韧性,还是反映了晚期癌症病例就诊的延迟。这些数据对于制定未来的癌症治疗和康复策略非常重要。
{"title":"Changes in New Patient Consultations During the COVID-19 Pandemic at a Canadian Comprehensive Cancer Center.","authors":"Carly C Barron, Tyler Pittman, Wei Xu, Mary Madunic, Niki Agelastos, David Goldstein, James Brierley, Monika K Krzyzanowska","doi":"10.6004/jnccn.2024.7003","DOIUrl":"10.6004/jnccn.2024.7003","url":null,"abstract":"<p><strong>Background: </strong>The impact of COVID-19 pandemic-related disruptions on cancer services is emerging. We evaluated the impact of the first 2 years of the pandemic on new patient consultations for all cancers at a comprehensive cancer center within a publicly funded health care system and assessed whether there was evidence of stage shift.</p><p><strong>Methods: </strong>We performed a retrospective study using the Princess Margaret Cancer Registry. New consultations with medical, radiation, or surgical oncology were categorized by year and quarter. Logistic regression was used to assess the effect of period before and during the COVID-19 pandemic on cancer stage at consultation, adjusting for age, sex, and diagnosis location (our hospital network vs elsewhere).</p><p><strong>Results: </strong>In all, 53,759 new patient consultations occurred from January 1, 2018, to June 30, 2022. After the pandemic was declared, there was a decrease in all types of consultations by 43.3% in the second quarter of 2020, and referral volumes did not recover during the first year. There was no evidence of stage shift for all cancer types during the later quarters of the pandemic for the overall population.</p><p><strong>Conclusions: </strong>New patient consultations decreased across cancer stages, referral type, and most disease sites at our tertiary cancer center. We did not observe evidence of stage shift in this population. Further research is needed to determine whether this reflects the resilience of our health care system in maintaining cancer services or a delay in the presentation of advanced cancer cases. These data are important for shaping future cancer care delivery and recovery strategies.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults. 治疗儿童、青少年和年轻人中复发/难治性 B 细胞非霍奇金淋巴瘤。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-18 DOI: 10.6004/jnccn.2024.7006
Aliza Gardenswartz, Mitchell S Cairo

Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody-drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.

尽管接受化学免疫疗法治疗的成熟B细胞非霍奇金淋巴瘤(B-NHL)儿童、青少年和年轻成人(CAYAs)治愈率极高,但复发/难治B-NHL的CAYAs仍然难以治疗,预后不佳。复发和后续治疗管理没有标准化。针对 B-NHL 的活性药物种类在不断增加,包括抗体药物共轭物、单克隆抗体、检查点抑制剂、T 细胞诱导剂、CAR T 细胞、CAR-自然杀伤(CAR-NK)细胞和细胞信号抑制剂。本文回顾了这一难治人群目前的管理实践和新型疗法。
{"title":"Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults.","authors":"Aliza Gardenswartz, Mitchell S Cairo","doi":"10.6004/jnccn.2024.7006","DOIUrl":"10.6004/jnccn.2024.7006","url":null,"abstract":"<p><p>Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody-drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. 遗传性癌症诊所提高了对 NCCN 胰腺癌基因检测指南的依从性。
IF 14.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-18 DOI: 10.6004/jnccn.2023.7333
Claudia Rosso, Naomie Devico Marciano, Deepika Nathan, Wen-Pin Chen, Christine E McLaren, Kathryn E Osann, Pamela L Flodman, May T Cho, Fa-Chyi Lee, Farshid Dayyani, Jason A Zell, Jennifer B Valerin

Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC).

Methods: We conducted a single-institution retrospective analysis of patients diagnosed with PDAC from June 2017 through December 2021 at University of California, Irvine. We compared rates of genetics referral among patients in different diagnostic eras: the 18-month period before the NCCN Guideline change (pre-NCCN era: June 2017 through November 2018), 14 months following the change (post-NCCN era: December 2018 through January 2020), and 18 months after the creation of an HCC (HCC era: June 2020 through December 2021). Family and personal cancer history, genetics referral patterns, and results of GC were recorded. Data were compared using chi-square, Fisher exact, and multivariate analyses.

Results: A total of 335 patients were treated for PDAC (123 pre-NCCN, 109 post-NCCN, and 103 HCC) at University of California, Irvine. Demographics across groups were comparable. Prior to the guideline changes, 30% were referred to GC compared with 54.7% in the post-NCCN era. After the implementation of the HCC, 77.4% were referred to GC (P<.0001). The odds ratio (OR) for referral to GC among patients with a positive family history of cancer progressively decreased following the change (pre-NCCN era: OR, 11.90 [95% CI, 3.00-80.14]; post-NCCN era: OR, 3.39 [95% CI, 1.13-10.76]; HCC era: OR, 3.11 [95% CI, 0.95-10.16]).

Conclusions: The 2018 updates to the NCCN Guidelines for PDAC recommending germline testing for all patients with PDAC significantly increased GC referral rates at our academic medical center. Implementation of an HCC further boosted compliance with guidelines.

背景:胰腺导管腺癌(PDAC)预后较差,5年总生存率仅为10%。2018 年 11 月,NCCN 建议所有 PDAC 患者接受遗传咨询(GC)和种系检测,无论是否有家族史。我们假设,在指南发生这一变化后,无论推测的预测因素如何,PDAC 患者更有可能被转介接受检测,而在遗传性癌症诊所(HCC)实施后,患者的依从性将进一步提高:我们对加利福尼亚大学欧文分校 2017 年 6 月至 2021 年 12 月期间诊断为 PDAC 的患者进行了单机构回顾性分析。我们比较了不同诊断时代患者的遗传学转诊率:NCCN 指南变更前的 18 个月(NCCN 前时代:2017 年 6 月至 2018 年 11 月)、NCCN 指南变更后的 14 个月(NCCN 后时代:2018 年 12 月至 2020 年 1 月)以及 HCC 成立后的 18 个月(HCC 时代:2020 年 6 月至 2021 年 12 月)。记录了家族和个人癌症病史、遗传学转诊模式以及 GC 结果。采用秩方、费雪精确和多变量分析对数据进行比较:加州大学欧文分校共有 335 名 PDAC 患者接受了治疗(123 名 NCCN 前患者、109 名 NCCN 后患者和 103 名 HCC 患者)。各组患者的人口统计学特征相当。在指南修改之前,30%的患者被转诊至GC,而在NCCN之后,这一比例为54.7%。在 HCC 实施后,77.4% 的患者被转诊至 GC(PConclusions:2018 年更新的 NCCN PDAC 指南建议对所有 PDAC 患者进行种系检测,这大大提高了我们学术医疗中心的 GC 转诊率。HCC的实施进一步提高了指南的依从性。
{"title":"Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.","authors":"Claudia Rosso, Naomie Devico Marciano, Deepika Nathan, Wen-Pin Chen, Christine E McLaren, Kathryn E Osann, Pamela L Flodman, May T Cho, Fa-Chyi Lee, Farshid Dayyani, Jason A Zell, Jennifer B Valerin","doi":"10.6004/jnccn.2023.7333","DOIUrl":"10.6004/jnccn.2023.7333","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC).</p><p><strong>Methods: </strong>We conducted a single-institution retrospective analysis of patients diagnosed with PDAC from June 2017 through December 2021 at University of California, Irvine. We compared rates of genetics referral among patients in different diagnostic eras: the 18-month period before the NCCN Guideline change (pre-NCCN era: June 2017 through November 2018), 14 months following the change (post-NCCN era: December 2018 through January 2020), and 18 months after the creation of an HCC (HCC era: June 2020 through December 2021). Family and personal cancer history, genetics referral patterns, and results of GC were recorded. Data were compared using chi-square, Fisher exact, and multivariate analyses.</p><p><strong>Results: </strong>A total of 335 patients were treated for PDAC (123 pre-NCCN, 109 post-NCCN, and 103 HCC) at University of California, Irvine. Demographics across groups were comparable. Prior to the guideline changes, 30% were referred to GC compared with 54.7% in the post-NCCN era. After the implementation of the HCC, 77.4% were referred to GC (P<.0001). The odds ratio (OR) for referral to GC among patients with a positive family history of cancer progressively decreased following the change (pre-NCCN era: OR, 11.90 [95% CI, 3.00-80.14]; post-NCCN era: OR, 3.39 [95% CI, 1.13-10.76]; HCC era: OR, 3.11 [95% CI, 0.95-10.16]).</p><p><strong>Conclusions: </strong>The 2018 updates to the NCCN Guidelines for PDAC recommending germline testing for all patients with PDAC significantly increased GC referral rates at our academic medical center. Implementation of an HCC further boosted compliance with guidelines.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":null,"pages":null},"PeriodicalIF":14.8,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the National Comprehensive Cancer Network
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1